These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 16546306

  • 21. Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6.
    Griffin KF, Eyles JE, Spiers ID, Alpar HO, Williamson ED.
    Vaccine; 2002 Nov 01; 20(31-32):3650-7. PubMed ID: 12399192
    [Abstract] [Full Text] [Related]

  • 22. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.
    Khan AA, Babu JP, Gupta G, Rao DN.
    Vaccine; 2008 Jan 17; 26(3):316-32. PubMed ID: 18096277
    [Abstract] [Full Text] [Related]

  • 23. The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses.
    Elvin SJ, Williamson ED.
    Microb Pathog; 2000 Oct 17; 29(4):223-30. PubMed ID: 10993741
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse.
    Eyles JE, Sharp GJ, Williamson ED, Spiers ID, Alpar HO.
    Vaccine; 1998 Apr 17; 16(7):698-707. PubMed ID: 9562689
    [Abstract] [Full Text] [Related]

  • 26. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu.
    Carpenter ZK, Williamson ED, Eyles JE.
    J Control Release; 2005 May 05; 104(1):67-77. PubMed ID: 15866335
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, Lowell GH, Burt DS.
    Vaccine; 2006 Mar 06; 24(10):1625-32. PubMed ID: 16243411
    [Abstract] [Full Text] [Related]

  • 30. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
    Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Mett V, Yusibov V.
    Vaccine; 2009 May 26; 27(25-26):3471-4. PubMed ID: 19200825
    [Abstract] [Full Text] [Related]

  • 31. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
    Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C, Worsham P, Pullen JK, Ribot W, Hines H, Smith L, Heath DG, Adamovicz JJ.
    Biotechnol Prog; 2005 May 26; 21(5):1490-510. PubMed ID: 16209555
    [Abstract] [Full Text] [Related]

  • 32. A plant-produced plague vaccine candidate confers protection to monkeys.
    Mett V, Lyons J, Musiychuk K, Chichester JA, Brasil T, Couch R, Sherwood R, Palmer GA, Streatfield SJ, Yusibov V.
    Vaccine; 2007 Apr 20; 25(16):3014-7. PubMed ID: 17287055
    [Abstract] [Full Text] [Related]

  • 33. The search for early markers of plague: evidence for accumulation of soluble Yersinia pestis LcrV in bubonic and pneumonic mouse models of disease.
    Flashner Y, Fisher M, Tidhar A, Mechaly A, Gur D, Halperin G, Zahavy E, Mamroud E, Cohen S.
    FEMS Immunol Med Microbiol; 2010 Jul 01; 59(2):197-206. PubMed ID: 20497221
    [Abstract] [Full Text] [Related]

  • 34. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
    Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW.
    Microb Pathog; 2008 Feb 01; 44(2):164-8. PubMed ID: 17904793
    [Abstract] [Full Text] [Related]

  • 35. Small protective fragments of the Yersinia pestis V antigen.
    Vernazza C, Lingard B, Flick-Smith HC, Baillie LW, Hill J, Atkins HS.
    Vaccine; 2009 May 11; 27(21):2775-80. PubMed ID: 19366573
    [Abstract] [Full Text] [Related]

  • 36. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 37. Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague.
    Reed DS, Martinez MJ.
    Vaccine; 2006 Mar 20; 24(13):2283-9. PubMed ID: 16377037
    [Abstract] [Full Text] [Related]

  • 38. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.
    Eyles JE, Williamson ED, Spiers ID, Alpar HO.
    Vaccine; 2000 Aug 01; 18(28):3266-71. PubMed ID: 10869771
    [Abstract] [Full Text] [Related]

  • 39. LcrV plague vaccine with altered immunomodulatory properties.
    Overheim KA, Depaolo RW, Debord KL, Morrin EM, Anderson DM, Green NM, Brubaker RR, Jabri B, Schneewind O.
    Infect Immun; 2005 Aug 01; 73(8):5152-9. PubMed ID: 16041032
    [Abstract] [Full Text] [Related]

  • 40. [Protective activity of the recombinant strain Salmonella minnesota R595/GSA, synthesizing the plague capsule antigen in experimental plague in mice].
    Gremiakova TA, Stepanshina VN, Korobova OV, Anisimov GA.
    Mol Gen Mikrobiol Virusol; 1994 Aug 01; (1):23-6. PubMed ID: 8133846
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.